The Latest Breaking News from Pfizer

Australia has used less than a quarter of the hundreds of millions of COVID-19 vaccine doses it bought. What will happen to the rest?

ORLANDO, Fla. — Scientists have suggested that once vaccines and treatment for COVID-19 became widely available, a surge might not require more than the basic precautions practiced during flu season. With the development of vaccines, pre-exposure treatment such as Evushield and post-exposure treatment such as Paxlovid, it’s natural to ask…

Shares of Novavax (NASDAQ: NVAX) fell 26.2% on Jul 14, after the European Medicines Agency's (TSE: EMA) Pharmacovigilance Risk Assessment Committee ("PRAC") updated the product label of Nuvaxovid, the company's COVID-19 vaccine, to include some potential side effects like severe aller

Looking for more ways to play Tesla stock? In a U.S. industry first, AXS Investments debuted an ETF that tracks just that one popular stock.

The BA.5 strain represented 65% of cases from July 3 to 9, according to data from the Centers of Disease Control and Prevention.

Omicron is now the dominant strain of COVID-19 around the world and boosters targeting this variant are getting closer to being released.

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 11 strange trades.

The European Union's ombudswoman criticised the European Commission for failing to find and publish text messages between the executive's president, Ursula von der Leyen, and the head of Pfizer negotiating a massive COVID-19 vaccine deal.

European Commission ‘gave no good reason’ why its president’s messages with Pfizer were not released